|4Aug 31, 6:25 PM ET

Sagent Pharmaceuticals, Inc. 4

4 · Sagent Pharmaceuticals, Inc. · Filed Aug 31, 2016

Insider Transaction Report

Form 4
Period: 2016-08-29
Jonathon M Singer
Chief Financial Officer
Transactions
  • Disposition from Tender

    Common Stock

    2016-08-29$21.75/sh7,857$170,89027,206 total
  • Disposition to Issuer

    Common Stock

    2016-08-29$21.75/sh27,206$591,7310 total
  • Disposition to Issuer

    Common Stock

    2016-08-29$21.75/sh3,665$79,71435,063 total
  • Disposition to Issuer

    Stock Option to Buy

    2016-08-29$7.14/sh34,783$248,3510 total
    Exercise: $14.61Exp: 2026-02-22Common Stock (34,783 underlying)
  • Disposition to Issuer

    Stock Option to Buy

    2016-08-29$1.59/sh10,638$16,9140 total
    Exercise: $20.16Exp: 2024-02-18Common Stock (10,638 underlying)
  • Disposition to Issuer

    Stock Option to Buy

    2016-08-29$1.65/sh55,000$90,7500 total
    Exercise: $20.10Exp: 2021-09-19Common Stock (55,000 underlying)
  • Disposition to Issuer

    Stock Option to Buy

    2016-08-29$5.30/sh12,067$63,9550 total
    Exercise: $16.45Exp: 2023-02-21Common Stock (12,067 underlying)
Footnotes (7)
  • [F1]Pursuant to the Agreement and Plan of Merger by and among Nichi-Iko Pharmaceutical Co. Ltd., Shepard Vision, Inc. and Sagent Pharmaceuticals, Inc. (the "Merger Agreement"), these shares were canceled and converted into the right to receive $21.75 per share in cash, without interest, less any applicable withholding taxes (the "Consideration").
  • [F2]Pursuant to the Merger Agreement, these shares were disposed of in a cash tender offer by Shepard Vision, Inc. to acquire common stock of Sagent Pharmaceuticals, Inc. in exchange for the Consideration.
  • [F3]Pursuant to the Merger Agreement, these restricted shares were canceled and converted into the right to receive the Consideration.
  • [F4]Represents the disposition of options, which provided for vesting in four equal installments beginning February 22, 2017. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $7.14 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
  • [F5]Represents the disposition of options, which provided for vesting in four equal installments beginning February 18, 2015. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1.59 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
  • [F6]Represents the disposition of options, which provided for vesting in four equal installments beginning February 21, 2014. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $5.30 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.
  • [F7]Represents the disposition of options, which provided for vesting in four equal installments beginning September 19, 2012. The options were cancelled pursuant to the Merger Agreement in exchange for a cash payment of $1.65 per share subject to the option. This per share price represents the difference between the applicable exercise price of the option and the Consideration.

Documents

1 file
  • 4
    doc4.xmlPrimary

    FORM 4 SUBMISSION